TheraRadar
Data updated: May 26, 2026

IZBA (travoprost)

Ophthalmology Approved 2014-05-15
1
Indication
--
Phase 3 Trials
12
Years on Market

Details

Status
Discontinued
First Approved
2014-05-15
Patent Cliff
2029

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: TRAVOPROST

IZBA Approval History

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2014 to 2021
Jun 2021 SUPPL
Label · Labeling
May 2014 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What IZBA Treats

1 FDA approvals

Originally approved for its first indication in 2014 .

  • Other (1)
📋

Clinical Trial Registry

8 trials
Trial Sponsor ID Phase Status Title
NCT02390284 STOP-RGCD results posted 20140587 R01EY014957 Ph 3 terminated Stop Retinal Ganglion Cell Dysfunction Study
NCT04615403 results posted IDOS-106-EXCH Ph 2 completed Study of Exchange of Travoprost Intraocular Implant
NCT01444040 GCF-027 Ph 4 completed Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost
NCT02914509 results posted OTX-16-002 Ph 3 completed Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
NCT01443988 GCF-022 Ph 4 completed Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost
NCT01315574 BAK results posted 11-007H Ph 4 terminated Effects of Anti-Glaucoma Medications on the Ocular Surface
NCT02105311 EC57-020-02-1 Ph 4 completed Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure
NCT00705757 results posted Pfizer GA6111AX Ph 4 completed The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IZBA FDA Label Details

View full patent landscape →
4 OB patents · 1 families · 55 international docs across 24 countries

IZBA Patents & Exclusivity

Latest Patent: Oct 2029

Patents (4 active)

US8722735 Expires Oct 10, 2029
US8178582 Expires Oct 10, 2029
US8754123 Expires May 19, 2029
US9144561 Expires Mar 13, 2029
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for IZBA

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2029
  • 4 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.